Abstract
About this talk
Introduction
Niosomal nanocarriers are promising platforms for drug and gene delivery, yet conventional fabrication methods suffer from poor reproducibility, limited size control, and batch variability. Microfluidic mixing enables precise control over vesicle self-assembly; however, systematic understanding of how microfluidic process parameters govern niosome structure and biological performance across diverse payload classes remains limited. This study addresses this gap using microfluidic manufacturing of niosomes loaded with structurally distinct therapeutics.
Methods
Niosomes composed of non-ionic surfactants and cholesterol were produced using continuous-flow microfluidic mixing in a staggered herringbone micromixer. Formulations were systematically optimized by varying organic solvent systems, hydration media, flow-rate ratios (FRR), and total flow rates (TFR). Particle size, polydispersity index, zeta potential, encapsulation efficiency, release kinetics, and biological performance were evaluated. Hydrophobic and hydrophilic drugs, peptides, protein antigens, and siRNA were encapsulated. Selected formulations were benchmarked against niosomes prepared by conventional thin-film hydration and heating methods.
Results
Microfluidic mixing reproducibly generated monodisperse niosomes with sizes ranging from 50–300 nm and PDI ≤0.15, demonstrating excellent batch-to-batch consistency. Encapsulation efficiencies varied from 20–100%, depending on payload physicochemical properties [1, 2]. Drug-loaded niosomes exhibited sustained release profiles and enhanced cytotoxic activity across multiple cancer cell models. Systematic modulation of aqueous and organic phases revealed distinct process-dependent effects on particle size, surface charge, polydispersity, and encapsulation efficiency, defining critical process–property relationships [3]. Cationic siRNA-loaded niosomes showed efficient cellular uptake and robust c-myc gene silencing with minimal carrier-associated toxicity. Compared to conventional methods, microfluidic fabrication consistently yielded superior size control, stability, and encapsulation efficiency across all payload classes.
Conclusion
This work establishes microfluidic mixing as a robust, scalable, and formulation-agnostic platform for niosome manufacturing. Quantitative process–structure–function relationships are defined, enabling rational design of niosomal carriers for controlled drug and gene delivery and supporting future translational and manufacturing applications.
Learning Objectives
- Explain how microfluidic parameters control niosome size, uniformity, and encapsulation.
- Analyze relationships between flow conditions, solvents, and niosome physicochemical properties.
- Compare performance of microfluidic niosomes loaded with drugs, peptides, and siRNA.
Speaker
About the speaker

